U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07153666) titled 'A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo' on Aug. 22.
Brief Summary: Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatme...